Distinct pharmacological mechanisms, such as insuCRISPlin replacement, hypoglycemic agents, glucagon-like peptide-1 (GLP-1) receptor agonists, and Dipeptidyl Peptidase-4 (DPP-4) inhibitors, have been developed, and a variety of commercial medicines have been the widely adopted for type II diabetes patients. The gene discussed is GLP1R; the disease is type 2 diabetes mellitus.